We describe the landscape of genomic alterations in cutaneous melanomas through DNA,
RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 …

Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …

Treatment of cancer has been revolutionized by immune checkpoint blockade therapies.
Despite the high rate of response in advanced melanoma, the majority of patients succumb to …

Immune checkpoint inhibitors (ICIs) produce durable responses in some melanoma patients,
but many patients derive no clinical benefit, and the molecular underpinnings of such …

Abstract Treatment with immune checkpoint blockade (CPB) therapies often leads to
prolonged responses in patients with metastatic melanoma, but the common mechanisms of …

The identification of multipotential mesenchymal stem cells (MSCs) derived from adult human
tissues, including bone marrow stroma and a number of connective tissues, has provided …

Multipotential adult mesenchymal stem cells (MSCs) are able to differentiate along several
known lineages, and lineage commitment is tightly regulated through specific cellular …

Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses 1 , 2 – 3 ; however, the relationship between phenotypic …

Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd)
tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To …

Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can
induce durable tumor regressions in some patients. To enhance the efficacy of existing …